July 2013

A 2009 article in Epilepsiai showed clearly that “adverse pregnancy and birth outcome in women with epilepsy is mainly confined to AED-exposed pregnancies.”  This article, by G. Veiby et al., reviewed records from “the compulsory Medical Birth Registry of Norway, [and] all 2,861 deliveries by women with epilepsy recorded from 1999-2005 were compared to all 369,267 nonepilepsy deliveries in the same period.”

About two-thirds of women with epilepsy who gave birth during this period used no antiepileptic drugs (AEDs) during pregnancy.  Researchers compared the vitality of the remaining 961 children born to mothers who used antiepileptic drugs during pregnancy to the control group of children whose mothers did not have epilepsy.  Overall, children whose mothers used antiepileptic drugs “were more often preterm,” “and more often had birth weight <2,500 g” (5.5lbs), “head circumference <2.5 percentile, “low Apgar score.” “Small-for-gestational-age (SGA) infants (<10 percentile) occurred more frequently in both AED-exposed (p = 0.05) and unexposed (p = 0.02) epilepsy-pregnancies.”

The epilepsy drug that was most highly associated with major congenital malformations  was valproate, the active ingredient in Depacon, Depakene, Depakote, and others.  Children born to mothers who used Depacon during pregnancy were found to be twice as likely to be born with major congenital malformations.

Due the the fact that the manufacturer of Depacon, Depakene, and Depakote has failed to warn women of the risks that valproate use poses to their developing child, a number of Depacon, Depakene, and Depakote birth defect lawsuits have been filed around the country.

Though this study does not detail specific birth defects associated with valproate, many other studies do.  For more information on the craniofacial birth defects, neurological birth defects, and cardiovascular birth defects associated with sodium valproate (Depacon, Depakene, Depakote), follow the links above.

If you have any questions about Depacon or for Depacon lawsuit information, you may reach our offices by phone at (855) 452-5529 or by e-mail at justinian@dangerousdrugs.us.

In 1998, a report published Annals of Pharmacotherapy by DP Lewis et al. aimed to illustrate the importance of folic acid during pregnancy, and as antiepileptic drugs (AEDs) lower serum folic acid levels, this report also illustrates that AEDs can be dangerous for a developing fetus.   The main ingredient in most AEDs used today is sodium valproate (also “valproic acid,” “sodium divalproex”).

To gather data, this research team used computerized international medical literature databases to gather “journal articles published through December 1997. … Search terms included phenytoin, carbamazepine, phenobarbital, primidone, valproic acid, oral contraceptives, clomiphene, drug-induced abnormalities, spina bifida, anencephaly, neural tube defect, folate, folic acid, and folic acid deficiency.” (emphasis added)

Once Lewis et al. had gathered and a reviewed number of relevant historical studies about the safety of AEDs and their use in pregnancy, the authors concluded that “Women receiving folate-lowering drugs may be at increased risk of adverse pregnancy outcomes. Therefore, epileptic women contemplating pregnancy should be treated with the minimum number of folate-lowering drugs possible and receive folic acid supplementation.” (emphasis added)

Due to the fact that many women and women’s health professionals were not made aware of the risks associated with sodium valproate (Depacon, others) a number of Depacon lawsuits are currently being filed.

If you or a loved one used Depacon during pregnancy and your child was born with a birth defect, you may be entitled to significant financial compensation for the injury sustained to your family through no fault of your own.

For more information on Depacon or Depacon lawsuits, please do not hesitate to contact our team of Depacon lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

In 1992, medical researchers AV Delagdo-Escueta and D Janz reported that “All women with epilepsy who are of childbearing age should be advised (preferably before conception) that the incidence of malformations in infants of mothers with epilepsy who are treated with antiepileptic drugs (AEDs) is two or three times that of infants of mothers without epilepsy.” (emphasis added)

At this time, researchers “do not know which of the four major AEDs (phenytoin, carbamazepine, valproate, and phenobarbital) [was] the most teratogenic,” (emphasis added) and while this question remains unresolved, sodium valproate (Depacon, others) in particular has been associated with a significant increase in rates of cardiovascular, neurologic, and craniofacial birth defects.

Thankfully, Delgado-Escueta et al. (1992) also stated that “Despite the small but significant risks, more than 90% of women with epilepsy who receive AEDs during pregnancy will deliver normal children free of birth defects.”  For more detail on the Delgado-Escueta et al. (1992) research showing the danger of sodium valproate and other AEDs, follow the link above.

Due to the fact that the manufacturer of the popular, sodium valproate-containing AED, Depacon, has time and again failed to make its customers aware of the risks of prenatal Depacon exposure, a number of Depacon lawsuits have been filed across the country.

If you or a loved one used Depacon during pregnancy and your child was born with a congenital malformation, please do not hesitate to contact our team of Depacon lawyers as you may be entitled to significant financial compensation.

For more information on Depacon or Depacon lawsuits, you may reach our offices by phone at (855) 452-5529 or by e-mail at justinian@dangerousdrugs.us.  We have the experiences, resources, and skills required to fight even the largest pharmaceutical companies and win the justice you deserve.

Call today and see how we can help!

Our Depacon Lawsuit Information page is a great place to start if you have more questions about Depacon.

Published in 2006, a paper by Shi Wu Wen, MB, PhD, et al. titled “Selective serotonin reuptake inhibitors and adverse pregnancy outcomes” published in The American Journal of Obstetrics and Gynecology aimed “to assess the safety of the use of selective serotonin reuptake inhibitors in pregnancy.”

The Wen et al. (2006) study group included “972 pregnant women who had been given at least 1 selective serotonin reuptake inhibitor prescription in the year before delivery and 3878 pregnant women who did not receive selective serotonin reuptake inhibitors and who were matched by the year of the infant’s birth, the type of institute at birth, and the mother’s postal code from 1990 to 2000 in the Canadian province of Saskatchewan.”

Results showed that risk of low birth weight was 58% higher for children with prenatal SSRI exposure.  Children exposed to SSRIs during pregnancy were also 57% more to be born preterm, had a 223% increased risk for fetal death, and nearly 400% more likely to suffer from seizures.

Since manufacturers of SSRI drugs have time and again failed to notify patients of the risks associated with their products, women all over the world have unknowingly placed their children at risk for major birth defects, and as such, a number of SSRI birth defects lawsuits have been filed.

If you or a loved one used SSRI drugs during pregnancy and your child was born with a congenital malformation, you may be entitled to financial compensation for injury endured by your family through no fault of your own.

For a free, no-obligation case consultation, or if you would like more information on SSRIs and birth defects, please do not hesitate to contact our team of SSRI birth defects lawyers at the information provided below.

At your convenience, you may reach our offices by phone at (855) 452-5529 or by e-mail at justinian@dangerousdrugs.us.  Call today and see how we can help!

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

In 2004, research by F. Yaris et al. published in Reproductive Toxicology evaluated the safety of newer antidepressants in pregnancy. To-date, a number of antidepressant drugs, especially SSRIs (Paxil, Prozac, Celexa, Effexor, others) have been associated with a range of life-threatening birth defects.

More information on SSRI and birth defects.

This Yaris et al. (2004) piece examined “590 cases exposed to drugs during pregnancy who were followed by our center, [of which,] 21 cases used newer antidepressants, i.e., venlafaxine, mirtazapine, nefazodone.”  The common names for these drugs are Effexor, Remeron, and Serzone, respectively.

While this study (only including 21 cases of children exposed to SSRIs in pregnancy) did not show evidence for the view that SSRIs cause birth defects, spontaneous abortion was observed in a child exposed to Effexor, Remeron, Alprazolam, Diazepam, and Trifluoperazine.

The problem with studies as small as this is that their results are often misleading.  This study did not show congenital abnormalities in children exposed to SSRIs, but that does not mean that SSRIs do not cause birth defects, it simply means that none were observed among these 21 children.

Other studies, however, show clear, significant, association between Effexor and birth defects.  For more detail on those studies showing the increased rate of birth defects among children exposed to Effexor, follow the preceding link.

Due to the fact that the manufacturers of Effexor and other SSRI drugs have failed to warn physicians and patients about the risks associated with their products, a number of SSRI birth defect lawsuits are currently being filed.

If you or a loved one used SSRIs during pregnancy, and your child was born with a birth defect, you may be entitled to significant financial compensation for injury to your family endured through no fault of your own.

For more information on Effexor and Effexor lawsuits, please do not hesitate to contact our team of Effexor lawyers at the information provided below.  We have the experience, resources, and skills required to bring you the justice you and your family deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Call today and see how we can help!

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

In an article published last year in The Journal of The American Medical Academy, by Mahyar Etminan et al. set out to “examine the association between use of oral fluoroquinolones and the risk of developing a retinal detachment.”  Oral fluoroquinolones (Cipro, others) are antibiotics used in a wide range of medical procedures, and have recently been associated with an increased risk for retinal detachment.  The authors of the study comment: “Despite numerous case reports of ocular toxicity, a pharmacoepidemiological study of their ocular safety, particularly retinal detachment, has not been performed.”

To gather data, Etminan et al. (2012) examined “a cohort of patients in British Columbia, Canada, who had visited an ophthalmologist between January 2000 and December 2007” and defined “retinal detachment cases” were defined as patients who had “retinal repair surgery within 14 days of a physician service.”

Here is what their research showed:

“Current use of fluoroquinolones was associated with a higher risk of developing a retinal detachment (3.3% of cases vs 0.6% of controls; adjusted rate ratio [ARR], 4.50 [95% CI, 3.56-5.70]).”

What this means is that Cipro use makes one 4.5 times as likely to experience retinal detachment than if one used another class of antibiotic drugs.  (“ARR” stands for “Adjusted Risk Rate.)

Another way the Etminan et al. (2012) data can be understood is as such: The general population experiences retinal detachment at a rate of 0.6%, while people who use Cipro experience retinal detachment at a rate of 3.3%.

Due to the fact that the manufacturer of Cipro failed to make physicians and patients aware of the association between Cipro and retinal detachment, a number of Cipro lawsuits are currently being filed.

If you or a loved one used Cipro and experienced retinal detachment, you may be entitled to significant financial compensation for injuries caused by no fault of your own.  For more information, or for a free, no-obligation case consultation, please do not hesitate to contact our team of Cipro lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Call today and see how we can help!

In 2011, R. Shallcross et al. published a report in Neurology that compared the safety of two antiepileptic drugs, levetiracetam and sodium valproate (Depacon Depakene, Depakote, others), for a developing fetus.  Shallcross et al. (2011) compared the health of 51 children that had been exposed to levetiracetam while in the womb to 44 children that had been exposed to sodium valproate.

After rigorous statistical analyses, Shalcross et al. (2011) found that children exposed to levetiracetam did not cause a significant drop in a child’s development quotient, while the development of 40% of children exposed to sodium valproate was “below average” after two years.

While this study shows that sodium valproate (Depacon, others) is more dangerous for a developing fetus than is levetiracetam, it does not fully illuminate the true danger of using sodium valproate while pregnant.

Since the publication of this study, a great deal of research has shown an association between Depacon and severe birth defects.  Cardiac birth defects, neurologic birth defects, and craniofacial birth defects have all been associated with prenatal exposure to Depacon.

Due to the fact that the manufacturer of Depacon has time and again failed to clearly warn the users of its product of the risks it carries for developing babies, a number of Depacon lawsuits have been filed around the country.

If you or a loved one used Depacon and your child was born with a congenital malformation, you may be entitled to significant financial compensation from the manufacturer of Depacon through a Depacon Lawsuit.

For more information on Depacon and Depacon lawsuits, please feel free to call or e-mail our team of Depacon lawyers at the information provided below.

(855) 452-5529

justinian@dangerousdrus.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

In April of this year, Journal of the American Medical Association published a case-controlled study, by Jakob Christensen, PhD et al., showing a clear association between prenatal sodium valproate (Depacon, Depakene, Depakote) exposure and increased risk of autism spectrum disorder and childhood autism.

Sodium valproate (also “valproic acid,” “divalproex sodium”) is the main ingredient in a number of antiepileptic medications on which more than 2 million Americans rely.

The Christensen et al. (2013) study analyzed “all children born alive in Denmark from 1996 to 2006” and “[Used national registers] to  identify children exposed to valproate during pregnancy and diagnosed with autism spectrum disorders (childhood autism [autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive developmental disorders).”

“Of 655 615 children born from 1996 through 2006, 5437 were identified with autism spectrum disorder, including 2067 with childhood autism.”  This places the overall rate of children born with autism (of any kind) at about 1%, a figure consistent with overall global rates.  Further statistical analysis showed that “the estimated absolute risk after 14 years of follow-up was 1.53%”

When Christensen et al. (2013) reviewed only children exposed to valproate during pregnancy, however, the overall rate of autism spectrum disorder was found to be about 4.42%.  This means that children exposed to valproate were 2.9 times as likely to be born with autism spectrum disorder than children not exposed to the drug during pregnancy.  Similar results were found for childhood autism.

This, however does not yet show whether valproate causes autism, for every woman taking valproate during pregnancy had epilepsy, and therefore it may have been simply that maternal epilepsy causes autism, and not sodium valproate.

So, with this in mind, Christensen et al. (2013) determined the rate for autism among women who were epileptic but did not use valproate during pregnancy.  The rate for autism among children born to these women dropped to 2.44%.  This more conclusively shows that sodium valproate is the culprit, and not maternal epilepsy.

The authors of this study conclude as follows: “Maternal use of valproate during pregnancy was associated with a significantly increased risk of autism spectrum disorder and childhood autism in the offspring, even after adjusting for maternal epilepsy. For women of childbearing potential who use antiepileptic medications, these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control.”

Due to the fact that the association between sodium valproate (Depacon) and autism spectrum disorder was not made clear to women who used Depacon during pregnancy, a number of Depacon lawsuits are currently being filed.

If you or a loved one used Depacon during pregnancy and your child was born with autism spectrum disorder or childhood autism, you may be entitled to significant financial compensation for undue suffering to your family.

For a more information, or a free, no-obligation case consultation, contact our team of Depacon lawyers.  At your convenience, you may reach our offices by phone at (855) 452-5529 or by e-mail at justinian@dangerousdrugs.us.

Our Depacon Lawsuit Information page is a great place to start if you have any more questions about Depacon.

A recent article published in The Journal of Research in Medical Sciences by Lelia Etemad et al. (2012) reviews the safety of prenatal exposure to antiepileptic drugs (AEDs).  With epilepsy affecting about 2.2 million Americans, this is a problem that must not be overlooked.

Though, states Etemad (2012), “the majority of children born to women with epilepsy are normal, they are at increased risk for malformations.”  Continuing, the author states “The incidence of major malformations in offspring of mothers with epilepsy who were treated with AEDs is higher than women with untreated epilepsy and in the general population. “

The congenital malformations that children born to mothers who used antiepileptic drugs during pregnancy such as Depacon, Depakene, and Depakote discussed in this study are “spina bifida, cleft palate, limb reduction defects, cardiac abnormalities, hypospadias, and gastrointestinal atresia.”

And while it is as of yet “uncertain” why an increased incidence of these diseases is observed in cases of prenatal exposure to sodium valproate, the fact remains that children born to mothers who used Depacon or drugs similar during pregnancy are more likely to be born with congenital malformations.

Due to the fact that many expecting mothers were unaware of these potential health consequences for their developing child, a number of Depacon lawsuits are currently being filed around the country.  If you used sodium valproate (Depakon) during pregnancy and your child was born with a birth defect, you too may be entitled to significant financial compensation for harm to your family.

For more information on Depacon or a Depacon lawsuit, or for a free, no-obligation case consultation, please do not hesitate to contact our team of Depacon lawyers.  We have both the experience and resources required to bring you the justice you and your loved ones deserve.

Call today at (855) 452-5529 or write us an e-mail at justinian@dangerousdrugs.us to see how we can help!

For more information on Depacon, the birth defects caused by Depacon, and Depacon lawsuits, please feel free to visit our Depacon Lawsuit Information page.

Published earlier this year in The Journal of the American Medical Association, a piece by Dr. Dennis P. Han et al. concludes that “patients taking oral fluoroquinolones were at a higher risk of developing a retinal detachment compared with nonusers, although the absolute risk for this condition was small.”  Oral fluoroquinolones, such as ciprofloxacin (Cipro), are a class of antibiotic drugs commonly-used during surgery.

Retinal detachment is a disease characterized by MedlinePlus, a prominent online medical encyclopedia curated by the National Library of Medicine and the National Institutes of Health, as “a separation of the light-sensitive membrane in the back of the eye (the retina) from its supporting layers.”

Here is a link to the MedlinePlus “Retinal Detachment” page.

And, according to Han et al. (2013), is an ailment with an overall frequency in the general population of about 0.6%.

Reviewing the medical records of nearly one million consenting American patients, Han and his team determined that while a patient is using fluoroquinolones, however, the risk for retinal detachment jumps to 3.3%.  That is, use of Cipro makes one 4.5 times as likely to experience retinal detachment.

Interestingly, risk for retinal detachment was not elevated by recent use nor past use.  Only current use of the drug was associated with an increased risk for retinal detachment.

Due to the fact that many users of Cipro and other oral fluoroquinolones were not made aware of the increased risk for retinal detachment before using the drug, a number of Cipro lawsuits are currently being filed.

If you or a loved one used Cipro and suffered retinal detachment, please do not hesitate to contact our team of Cirpo Retinal Detachment Lawyers for a free, no-obligation case consultation.

At your convenience, you may reach our offices by phone at (855) 452-5529 or by e-mail at justinian@dangerousdrugs.us.  Call today and see how we can help!